Rapid Molecular Test for Flu and COVID-19 Gets FDA Clearance and CLIA-Waiver
The point-of-care platform with multifunctional capabilities provides results in as little as 15 minutes.
The point-of-care platform with multifunctional capabilities provides results in as little as 15 minutes.
The FDA has granted Breakthrough Device Designations to two 15-minute rapid tests for detecting Candida auris and carbapenem-resistant Acinetobacter baumannii, both identified by WHO as critical priority pathogens.
The plasma-based test detects cell-free DNA from 14 mold species and delivers results in less than 24 hours, according to the company.
A field-deployable test demonstrates high sensitivity in identifying low-level infections that traditional methods miss, potentially supporting elimination efforts.
In silico analysis of 3,900 influenza sequences shows comparable sensitivity for the test against the subclade K variant currently circulating.
The Liaison Plex Gastrointestinal Flex Assay detects 24 targets and offers broad parasite coverage with pay-per-target flexibility.
Monash University study finds different testing algorithms work best for pregnant women versus men who have sex with men.